Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed in combating the world’s number one killer if it is integral to a ubiquitous, efficacious diagnostic programme.
Malaria, a disease caused by the Plasmodium parasite and transmitted through the bite of infected mosquitoes, has been a long-standing global health challenge. For over a century, scientists and researchers have been working tirelessly towards the development of an effective malaria vaccine. In recent years, significant progress has been made, culminating in the development of the Oxford Vaccine R21, which holds immense promise. However, despite this remarkable advancement in vaccinal protection, the need for diagnostics remains crucial to effectively combat and ultimately eradicate this devastating disease.
The Oxford Vaccine R21: A Breakthrough in Malaria Prevention
The Oxford Vaccine R21 represents a significant breakthrough in the quest to develop a malaria vaccine. Unlike its predecessors, which primarily targeted the malaria parasite when it was in the bloodstream, R21 employs a different strategy. It focuses on intercepting the parasite at an earlier stage of its lifecycle, shortly after a person has been bitten by an infected mosquito but before they manifest symptoms. This innovative approach aims to block the parasite’s entry into the liver, where it triggers the infection responsible for the debilitating symptoms associated with malaria.
The vaccine’s efficacy in targeting the early stages of the malaria parasite’s lifecycle is quite remarkable. By reducing the number of parasites and their genetic diversity at this critical juncture, R21 has demonstrated promising results in clinical trials, renewing hope for a more effective means of malaria prevention.
More recently, Ghana has become the first country to approve the R21 vaccine. The R21/Matrix-M vaccine, is now the first to exceed the World Health Organization’s target of 75% efficacy, and has been cleared for use by Ghana’s Food and Drugs Authority in children aged 5-36 months, the group at highest risk of death from malaria.
The Need for Continued Diagnostic Malaria Testing
While the development of the Oxford Vaccine R21 is undoubtedly a significant stride in malaria prevention, there is no justification for complacency in the fight against this disease. Diagnostic malaria testing remains indispensable for several compelling reasons:
1. Malaria Transmission Variability: Malaria transmission rates vary geographically and seasonally. In many endemic regions, transmission occurs year-round, but in others, it is seasonal. Diagnostic testing helps identify hotspots and high-transmission seasons, enabling targeted intervention strategies.
2. Asymptomatic Carriers: Malaria carriers can remain asymptomatic, serving as reservoirs for transmission. Diagnostic testing is essential to identify and treat these carriers, preventing further spread of the disease.
3. Vaccine Coverage Challenges: Achieving high vaccination coverage in malaria-endemic regions is a complex logistical challenge. Diagnostic testing ensures that individuals who have not yet received the vaccine or are ineligible for vaccination due to age or other factors receive timely diagnosis and treatment.
4. Antimalarial Drug Resistance: The emergence of drug-resistant malaria strains remains a grave concern. Diagnostic testing helps determine the most appropriate antimalarial treatment, reducing the risk of drug resistance development.
5. Surveillance and Monitoring: Malaria testing is integral to surveillance and monitoring efforts. Accurate data on the prevalence and distribution of the disease are vital for planning and evaluating malaria control programs.
6. Complementary Approach: The Oxford Vaccine R21, while promising, may not offer 100% protection. Diagnostic testing provides a complementary approach to identify breakthrough infections and ensure timely treatment.
The Oxford Vaccine R21 represents a significant step forward in the fight against malaria, offering hope for a future with reduced malaria-related suffering and deaths. However, it is crucial to recognise that the development of a malaria vaccine should not overshadow the continued importance of diagnostic malaria testing.
These tests play a pivotal role in identifying carriers, tracking transmission patterns, and ensuring comprehensive and effective malaria control strategies. To truly make malaria a disease of the past, we must embrace both vaccination and vigilant testing as integral components of a comprehensive malaria elimination campaign. Only through this combined effort can we hope to eradicate this age-old scourge and save countless lives.
The possibility of a malaria-free world within our lifetimes depends on every one of us. While politicians, scientists and public figures may be the most well-known allies, there are many people in malaria-burdened communities who dedicate their days to helping local people take preventative measures and protect themselves from malaria, and ensuring that people get tested and get the treatment they need.
All of us, no matter where we are in the world, can use our voices to raise awareness of malaria and demand an end to this often deadly and debilitating disease.
What are we doing to end malaria?
We at Erada Technology Alliance are developing SALVA! – the world’s first saliva-based rapid diagnostic test for malaria. Developed through research at Johns Hopkins University in the States, SALVA! delivers results in 5-20 minutes and can be administered by anyone – teachers, parents, or community leaders. Our Rapid Diagnostic Test will ensure that everyone can access a malaria test and take the burden off medical professionals, allowing them to focus on treatment.
You can find out more about SALVA! here.